In today’s recent session, 0.77 million shares of the EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) have been traded, and its beta is 1.72. Most recently the company’s share price was $17.30, and it changed around -$0.35 or -1.98% from the last close, which brings the market valuation of the company to $862.06M. EYPT at last check was trading at a discount to its 52-week high of $30.99, offering almost -79.13% off that amount. The share price’s 52-week low was $5.32, which indicates that the recent value has risen by an impressive 69.25% since then. We note from EyePoint Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 991.40K.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Instantly EYPT has been showing red trend so far today with a performance of -1.98% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -25.14% year-to-date, but still down -18.70% over the last five days. On the other hand, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is -26.13% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 30.8% from its current value. Analyst projections state that EYPT is forecast to be at a low of $25 and a high of $25.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
EyePoint Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 130.67 percent over the past six months and at a 4.95% annual growth rate that is well below the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 26.80% in revenue this quarter, and will report an increase of 26.20% in the next quarter. The year-over-year growth rate is expected to be -18.30%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $9.92 million in revenue for the current quarter. 9 analysts expect EyePoint Pharmaceuticals Inc to make $9.82 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $7.68 million and $9.11 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 29.10%. Forecasts for the next quarter put sales growth at 7.90%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 29.57%.
